44 results about "Potassium oxonate" patented technology

The invention relates to a capsule preparation containing tegafur, Jimeisita and Potassium Oxonate and a preparation method thereof, which is characterized in that the capsule preparation contains tegafu micropill, Jimeisita micropill and Potassium Oxonate micropill, wherein, the micropill is prepared from active drug ingredient, thinner, bond and surface active agent. The micropill is prepared with the extruding-rolling method, the centrifugal-fluidifying method, the pan coating pill floating method and the like, and then, other minor ingredients are added; finally, the capsule is filled. The capsule prepared with the preparation method can be steadily and quickly released in bodies, thus the drug stability is improved. The capsule has high dissolution rate and biological availability, and reduces adverse reaction of medicine.

The invention refers to a capsule preparation containing tegafur, gimeracil and potassium oxonate. The capsule preparation comprises the following components by weight parts: 20 parts of tegafur, 5-6 parts of gimeracil, 19-20 parts of potassium oxonate, 10-300 parts of lactose, and 0.9-5 parts of sodium dodecyl sulfate. According to the invention, the use level of the surfactant of sodium dodecylsulfate is greatly reduced on the premise of guaranteeing rapid dissolving-out of active components in the preparation, so that the irritation of the capsule preparation to the human gastrointestinaltract is decreased and the medicine compliance of a patient is increased.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.

The invention provides a method for refining high-purity potassium oxonate. The method is characterized by comprising the following steps: adding an potassium oxonate crude product into water; adding alkali into the water until the crude product is completely dissolved; adding a polar solvent into the solution; adjusting the pH of the solution to neutrality by acid; filtering and separating out crystal; and drying the crystal so as to obtain the high-purity potassium oxonate. The method has the advantages of simple operation, mild reaction condition, high yield, pure product and the like, and has yield over 90 percent, purity over 99.95 percent (detected by HPLC), and a single impurity peak reduced from 0.5 percent to below 0.05 percent.

The invention provides a synthesis technology for preparing oteracil potassium. With short reaction steps, the technology avoids the adoption of toxic and harmful bromine as an oxidant. The synthesis technology is characterized by comprising the following step of dissolving allantoin in a potassium hydroxide or potassium carbonate aqueous solution, wherein potassium iodide is used as a catalyst, and a pypocholoride aqueous solution is used as an oxidant. The method provided by the invention has the advantages of simplicity in operation, mild reaction conditions, high yield, high product purity and the like, and is suitable for industrial production of oteracil potassium.

The invention discloses a micro-pill containing tegafur, gimeracil and potassium oxonate, a capsule preparation and a preparation method for the micro-pill. The micro-pill comprises a tegafur drug layer-coated pill core, an isolation layer and a coating layer containing gimeracil and potassium oxonate. Tegafur, gimeracil and potassium oxonate are ground by airflow, the micro-pill is directly coated with a drug through an empty pill core, additional auxiliary materials are prepared into granules by a fluidized bed, the micro-pill is uniformly mixed with the additional auxiliary material granules, and a capsule is directly filled with a mixture. The prepared capsule is capable of enabling the drug to be stably and quickly released in bodies, remarkably improves the content uniformity and stability of the drug, has relatively high dissolution rate and bioavailability, reduces adverse drug reactions and can be commercially produced.

The invention discloses a compound shown as a formula I, and also discloses a preparation method of the compound and application of the compound as an impurity reference substance in check of potassium oxonate related substances. Due to the implementation of the compound, the quality of the potassium oxonate is effectively controlled, thus having significance to safe medication of the masses.

The invention relates to application of hirudin as a medicine for preventing and treating hyperuricemia, and discloses novel application of the hirudin for preparing a medicine for preventing and treating the hyperuricemia and diseases caused by the hyperuricemia; Kunming mice are induced by hypoxanthine and potassium oxonate to establish hyperuricemia models, and intervention effects of the hirudin on the hyperuricemia are observed. Research results show that the use of the hirudin for 12 consecutive days in the Kunming mice significantly reduces a serum uric acid level in hypoxanthine-induced hyperuricemia mice; the hirudin can also be used to prepare medicines for the hyperuricemia and the diseases caused by the hyperuricemia: obstructive sleep apnea and/or menopause syndrome, or hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, nephropathy, inflammation, infectious diseases, tumor lysis syndrome and other diseases. New application of the hirudin is openedup.

The invention relates to a construction method of an acute hyperuricemia mouse model. The method comprises the following steps: feeding a test mouse with a hairtail-containing feed every day, performing a 7-8-day modeling test; and in the last two days of the modeling test, respectively feeding the mouse with hypoxanthine and oteracil potassium every day. The method has the beneficial effects that: according to the construction method of the acute hyperuricemia mouse model, due to the fact that hypoxanthine, oteracil potassium and hairtail are adopted as the combination of a modeling agent, compared with the prior art, the model similar to the human body hyperuricemia attack process can be prepared through the synergistic effect of multiple machine modeling agents, and therefore the modeling time is shortened.